Tuesday, 17 November 2026 Every SEC filing alert, by company
ALFA USA Filings Every alert, straight from SEC EDGAR
News

Curis Inc

NASDAQ: CRIS · Life Sciences · 4 alerts · CIK 1108205

Share price
$0.4358Close, Nov 16
Market cap
$4.15M
Shares outstanding
9.51MLatest SEC cover page
Sector
Life Sciences
Industry
Biological Products, (No Diagnostic Substances)SIC 2836

Today's reference numbers: shares from the company's latest SEC cover page, price from the latest market close. Not a valuation or a recommendation. All Curis Inc filings on SEC EDGAR ↗

4:09 PM ET 10-Q
Financial Results

Curis Q3 2026 Results: Net Loss of $8.12M, Loss Widens

Curis, Inc. reported a total stockholders' equity of $2.55 million as of September 30, 2026, a decrease from $5.46 million at the end of 2025. The company continues to incur substantial losses, with an accumulated deficit reaching $1.29 billion, and management has identified conditions that raise substantial doubt about its ability to continue as a going concern.

Key figure
Net loss $8.12M
4:07 PM ET 8-K
Financial Results

Curis Financial Results

Curis reported financial results for the third quarter of 2026 and provided an operational update on its TakeAim CLL and TakeAim Lymphoma clinical trials. The company highlighted progress in combining emavusertib with BTK inhibitors for the treatment of CLL and PCNSL, with initial data from the TakeAim CLL study expected in December 2026.

Term
Q3 2026

“The excitement among clinicians and patients reflects the clear unmet need in both CLL and PCNSL, where emavusertib has the potential to change the treatment landscape when combined with approved BTK inhibitors.”

James Dentzer, Chief Executive Officer of Curis

Get Alerts

Get ALFA Finder alerts first

Real-time SEC filing alerts for US stocks are launching soon. Leave your details and we'll tell you the moment they go live.